2024 Presidential Election

As the 2024 presidential election evolves, ADVI experts are closely monitoring the healthcare issues with the potential for significant policy changes, including drug pricing regulations, healthcare reform, and shifts in regulatory priorities. Policies like the Inflation Reduction Act (IRA), are poised to have significant implications for many life sciences companies, impacting drug reimbursement, regulatory compliance obligations, market access dynamics.

Below are resources and insights with up-to-date information on the healthcare issues that may impact you the most leading up to and following the 2024 presidential election. ADVI experts will continue to monitor this evolving healthcare landscape to help you effectively adapt your strategies to navigate potential market volatility, regulatory uncertainties, and changes in consumer behavior effectively.

Get In Touch

ADVI experts share their thoughts on the most pressing healthcare issues discussed as part of the 2024 presidential State of the Union address. 
(March 8, 2024)

View Now

While healthcare hasn’t been a hot topic on the campaign trail, the outcome of this election will have significant implications for our clients as 2025 will be a big year for IRA implementation, PBM scrutiny, and state-level price-setting attempts.

Lindsay Bealor Greenleaf, JD, MBA, Solution Leader, Federal and State Policy

Seize The Opportunity

image description

Schedule a consultation on your current challenge.

Leverage our Expertise
image description

Submit an RFP and let’s determine how our team of experts can support your business.

Submit an RFP
image description

Get our incisive analysis delivered straight to your inbox.

Keep Me Informed

Reimbursement

Federal and State Policy